$ 15.9 billion worldwide in RF energy amplifiers by 2027


3 trading stocks at rock bottom; Analysts say “buy”

A new year, a new addition to the stock portfolio – what could be more useful? The right time to buy is of course when the stocks are at the low end. Buying low and selling high may be a bit trite, but it’s true, and the truth has staying power. But the markets are on the up. The NASDAQ rose 43% in 2020 and the S&P 500 was up 16%. In such a market environment, finding stocks stuck in the doldrums is harder than it looks. This is where the Wall Street pros can lend a hand. We used TipRanks’ database to identify three stocks that fit a profile: a stock price that has fallen over 30% in the past 12 months but has at least double-digit upside potential. According to analysts. Not to mention that everyone received a moderate or strong buy consensus rating. Esperion (ESPR) We’re starting Esperion, a company specializing in therapies to treat elevated low-density lipoprotein cholesterol levels – a major contributing factor to heart disease. The company’s lead product, bempedoic acid, is now available in tablet form under the brand names Nexletol and Nexlizet. In February 2020, both Nexletol and Nexlizet were approved as oral treatments for lowering LDL-C. Bempedoic acid remains in clinical trials for its effectiveness in reducing the risk of cardiovascular disease. The study, called CLEAR Outcomes, is a large-scale, long-term study that will enroll more than 14,000 patients with top-line data expected in the second half of 2022. The study includes 1,400 locations in 32 countries around the world peaked last February after FDA approvals, but the stock has fallen since then. Stocks are down 65% from their high. Coupled with the decline in its share value, the company saw sales decline from Q2 to Q3, with sales falling from $ 212 million to $ 3.8 million. Since the Q3 report, Esperion announced pricing of a $ 250 million senior subordinated debt offering at 4% maturity in 2025. The offer increases the availability of available capital for further work on its development pipeline and marketing efforts for Bempedoic acid. Chad Messer, who covers ESPR for Needham, sees the note offer as positive for Esperion. “We believe this cash position will be enough to support Esperion through 2021 and profitability in 2022. We believe this funding should help address concerns about Esperion’s bottom line. Despite a challenging market launch of NEXLETOL and NEXLIZET, product growth continued in the third quarter against the background of a shrinking LDL-C market. This growth trajectory suggests the potential for rapid acceleration if conditions improve, “wrote Messer. To this end, Messer rates ESPR shares with a strong Buy, and its price target of USD 158 suggests the stock will be this year Room for tremendous growth – up to 481% from wherever it is. (To see Messer’s track record, click here.) In total, Esperion has 6 recent ratings with a breakdown of 5 purchases and 1 hold to the stock one Shares Intercept Pharma (ICPT) Liver disease is a serious health threat and Intercept Pharma is focused at $ 27.16 with an average target price of $ 63.33, an uptrend of 133% for one year. (See ESPR stock analysis on TipRanks.) Developing therapies for some of the more dangerous chronic liver diseases, including i non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Intercept has a research pipeline based on FXR, a regulator of the bile acid pathways in the liver system, not only influencing bile acid metabolism, but also glucose and lipid metabolism, as well as inflammation and fibrosis in the liver. The lead compound obeticholic acid (OCA) is an analogue of the bile acid CDCA and as such may play a role in the FXR pathways and receptors involved in chronic liver disease. Treatment of liver disease by FXR biology has direct applications for PBC and shows promise for treatment complications in NASH.ICPT stocks, which fell sharply last summer when the FDA approved the company’s filing for OCA to treat NASH-related Liver fibrosis refused. This delays the drug’s potential entry into a lucrative market. There is currently no treatment for NASH, and the first drug to get approved will come out on top in reaching a market estimated to have potential annual sales of $ 2 billion to $ 5 billion. The impact on the stock is still being felt and ICPT remains at its 52-week low. In response, Intercept announced significant changes in top-level management in December 2020 when CEO and President Mark Pruzanski announced that he would be stepping down effective January 1 of that year. He will be replaced by Jerome Durso, former COO of the company, who will also take up a position on the Board of Directors. Pruzanski will continue to act as a consultant and serve as a director on the company’s board of directors. Yasmeen Rahimi, Analyst at Piper Sandler, delves into Intercept’s continued efforts to expand the use of OCA and resubmit the new drug application to the FDA. She sees the change in leadership as part of this effort and writes: “[We] believe that Dr. Pruzanski’s commitment to liver space transformation remains strong and that he will continue to lead ICPT’s advances as an advisor and board member. Additionally, we have had the pleasure to work closely with Jerry Durso and believe that he will transform the company and guide ICPT’s success in growing the PBC market and leading the way to the potential approval and commercial introduction of OCA in NASH. “Rahimi takes a long time. short-term bullish stance on ICPT, which gives the stock an overweight (i.e. buy) rating and a price target of $ 82. This number shows an impressive upward trend of 220% for the next 12 months. (To see Rahimi’s track record, click here.) Wall Street is a little more divided on the drug maker. ICPT’s moderate buying consensus rating is based on 17 ratings including 8 buys and 9 holds. The stock is priced at $ 25.82, and the average target price of $ 59.19 suggests upside potential of 132% over the next 12 months. (See ICPT stock analysis on TipRanks) Gilead Sciences (GILD) Gilead had a year like fireworks – fast up and fast down. The gains came in 1H20 when it was discovered that the company’s antiviral drug Remdesivir would become a primary treatment for COVID-19. By November, even though remdesivir had been approved, the World Health Organization (WHO) was recommending the use of remdesivir, and the COVID vaccines currently on the market have made remdesivir irrelevant to the pandemic. This was just one of Gilead’s recent headwinds. The company worked with Galapagos (GLPG) to develop filgotinib for the treatment of rheumatoid arthritis. While the drug received EU and Japanese approvals in September 2020, the FDA denied approval and Gilead announced in December that it would halt US development efforts for the drug. Even so, Gilead has a diverse and active research pipeline with over 70 research candidates at various stages of development and approval for a variety of diseases and conditions, including HIV / AIDS, inflammatory and respiratory diseases, cardiovascular disease and hematology / oncology. On a positive note, Gilead posted earnings above estimates in the third quarter, with sales of $ 6.58 billion beating forecast 6% and growing 17% year over year. The company has updated its full-year 2020 forecast for product sales from $ 23 billion to $ 23.5 billion. Among the bulls is Oppenheim-based analyst Hartaj Singh, who gives GILD shares an outperform rating (ie buy) and a price target of USD 100. Investors can achieve a 69% profit if the analyst’s thesis prevails. (To see Singh’s track record, click here.) Singh confirms his stance: “We continue to believe in our thesis of (1) a reliable remdesivir / other anti-SARS-CoV flare business, (2) a core business (HIV ) / Oncology / HCV) Low single digit growth over the next few years, (3) operational leverage for higher earnings growth, and (4) dividend yield of 3-4%. “What is the rest of the street thinking? With regard to the consensus distribution, the opinions of other analysts are more diverse. 10 buys, 12 holds and 1 sell result in a moderate buy consensus. Additionally, the average target price of $ 73.94 indicates upside potential of 25% from current levels. (See GILD stock analysis on TipRanks.) To find great ideas for trading rundown stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are exclusively those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

Comments are closed.